nab-paclitaxel (nab-P) + carboplatin (C) induction therapy in patients (Pts) with squamous (SCC) NSCLC: Interim safety results from the phase 3 ABOUND.sqm study
E. Kim(Harvard University), Jeanna Knoble(Columbus Community Clinical Oncology Program), Melissa L. Johnson(Tennessee Oncology), Teng Jin Ong, Nataliya Trunova, Davey B. Daniel(Tennessee Oncology), T. Chen, Michael McCleod(Sarah Cannon)
Cited by 0
Related Papers
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
|The Lancet Oncology|2019|1.7k
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|835
A Kinetic Model for Step Coverage by Atomic Layer Deposition in Narrow Holes or Trenches
|Chemical Vapor Deposition|2003|390